Systemic lupus erythematosus (SLE, or lupus) is a condition in which the immune system attacks healthy cells and tissues throughout the body, it is characterized by aberrant activity of the immune system, leading to variable clinical symptoms.

Case: A Moroccan 54 years old women presented a progressive dyspnea associated with palpitations with a history of hyperthyroidism, a pericardial effusion of great abundance punctured, the remainder of the diagnostic workup had revealed lupus erythematosus. The echocardiography found a global hypocontractility with an ejection fraction at 25%, moderate aortic regurgitation with an image of vegetation on the non-coronary cusp related to non-infectious endocarditis, andright ventricular dysfunction. Laboratory investigations revealed bycitopenia with high inflammatory markers, arenal dysfunction test result. Immunological tests showed a high positive antinuclear antibodies ans DNA antibodies. While hospitalization the patient presented an st segment elevation in the inferior derivation in relation with a coronary spasm and three days later a sudden hemiparesis with facial paralysis and aphasia, the emergency MRI objectified a cortical frontotemporal stroke, in the acute phase, the diagnosis of vasculitis of the central nervous system (CNS) was retained with ischemic and hemorrhagic lesions in favor of lupus vasculitis of the CNS.

Discussion: The case of our patient with Systemic lupus erythematosus involved: cardiac type of lupus myopericadtitis in biventricular dysfunction with LVEF: 25%,Normochromic normocytic anemia with positive coombs test and lymphopenia and thrombocytopenia ;lupus nephropathy satde IV ; Cerebral vasculitis. Cytopenias are common in patients with lupus, and moderate to severe lymphopenia is associated with high disease activity and organ damage.

The risk for ischemic stroke is higher in patient with SLE. The main cardiovascular diseases of SLE are valvular heart diseases associated with Libman-Sacks disease lesions; low ejection fraction is detected in the majority of the patients. Our patient had an ejection fraction around 25%. immunoglobulins (IVIGs) have been shown to improve cardiac function and mortality, in addition to the medical treatment of Heart failure.

Conclusion: Diagnosis of SLE can be challenging and while several classification criteria have been posed, their utility in the clinical setting is still a matter of debate. Despite several agents shown to be efficacious in the treatment of SLE, the disease still poses significant morbidity and mortality risk in patients.

Systemic lupus erythematosus (SLE, or lupus) is a condition in which the immune system attacks healthy cells and tissues throughout the body, it is characterized by aberrant activity of the immune system, leading to variable clinical symptoms.

Case: A Moroccan 54 years old women presented a progressive dyspnea associated with palpitations with a history of hyperthyroidism, a pericardial effusion of great abundance punctured, the remainder of the diagnostic workup had revealed lupus erythematosus. The echocardiography found a global hypocontractility with an ejection fraction at 25%, moderate aortic regurgitation with an image of vegetation on the non-coronary cusp related to non-infectious endocarditis, andright ventricular dysfunction. Laboratory investigations revealed bycitopenia with high inflammatory markers, arenal dysfunction test result. Immunological tests showed a high positive antinuclear antibodies ans DNA antibodies. While hospitalization the patient presented an st segment elevation in the inferior derivation in relation with a coronary spasm and three days later a sudden hemiparesis with facial paralysis and aphasia, the emergency MRI objectified a cortical frontotemporal stroke, in the acute phase, the diagnosis of vasculitis of the central nervous system (CNS) was retained with ischemic and hemorrhagic lesions in favor of lupus vasculitis of the CNS.

Discussion: The case of our patient with Systemic lupus erythematosus involved: cardiac type of lupus myopericadtitis in biventricular dysfunction with LVEF: 25%, Normochromic normocytic anemia with positive coombs test and lymphopenia and thrombocytopenia; lupus nephropathy satde IV ; Cerebral vasculitis. Cytopenias are common in patients with lupus, and moderate to severe lymphopenia is associated with high disease activity and organ damage.

The risk for ischemic stroke is higher in patient with SLE. The main cardiovascular diseases of SLE are valvular heart diseases associated with Libman-Sacks disease lesions; low ejection fraction is detected in the majority of the patients. Our patient had an ejection fraction around 25%. immunoglobulins (IVIGs) have been shown to improve cardiac function and mortality, in addition to the medical treatment of Heart failure.

Conclusion: Diagnosis of SLE can be challenging and while several classification criteria have been posed, their utility in the clinical setting is still a matter of debate. Despite several agents shown to be efficacious in the treatment of SLE, the disease still poses significant morbidity and mortality risk in patients.

Keywords: Cytopenias, Lymphopenia, Thrombocytopenia, Cardiovascular diseases, Libman-Sacks disease

Systemic lupus erythematosus (SLE, or lupus) is a condition in which the immune system attacks healthy cells and tissues throughout the body, it is characterized by aberrant activity of the immune system, leading to variable clinical symptoms, The initial presentation often is likea viral syndrome, arthropathy, which may include reducible ulnar deviation, swan neck deformities, or Z-shaped thumb, is present in 2.8%–4.3% of patients, Cutaneous anifestations are frequent and may occur in up to 75%–80% of patients, in addition to that,Systemic lupus may present in many other ways, the diagnosis should be considered when patients, particularly women of reproductive age, present with respiratory symptoms, such as cough, dyspnea, hemoptysis, or central nervous system (CNS) signs, such as headache, photophobia, or focal neurologic deficits, and cardiac involvement in up to 50% of cases [1-6].

A Moroccan 54 years old women who was a housewife and mother of two children, was admitted to the cardiological emergency room for progressive dyspnea associated with palpitations, She hada history of hyperthyroidism, and anhospitalization in the department for a pericardial effusion of great abundance punctured with withdrawal of 300cc of serohematic fluid, the remainder of the diagnostic workup had revealed lupus erythematosus for which she was put on immunosuppressant and plaquenil. On examination she was not febrile she had a heart rate at 107bpm, and a blood pressure at 130/ 80mmHg, Cardiac examination revealed a systolic mumrur at the mitral region. Pulmonary examination revealed bilateral decreased breath sounds with bilateral basal crackles. Lower limb edema was also noted, on the electrocardiogram we find a regular sinus rhythm at 107bpm, a PR fixed at 0.12sec, Normal heart axis, with negative T wave in lateral leads, the trans thoracic echocardiography found an undilated non-hypertrhophied Left ventricular (LV),seat of global hypocontractility with an ejection fraction at 25% of high filling pressures, a dilated atrial mass with a left atrium at 23cm² and a right atrium at 20cm², Moderate mitral regurgtitaion, moderate aortic regurgitation with an image of vegetation on the non-coronary cusp, right ventricular dysfunction with pulmonary hypertension at 55mmHg and minimal circumferential pericardial effusion [Figure 1].

Figure 1: Trans thoracic echocardiography showing an image of vegetation on the non-coronary cusp.

Laboratory investigations revealed bycitopenia with white blood cell count of 1.8 × 109 cells/L, platelet count of 100 × 109/L, hemoglobin 7.4 gm/dl with normal mean corpuscular volume and hematocrit, a positive Coombs test result, and high inflammatory markers (erythrocyte sedimentation rate [ESR], 80 mm/hour [normal range, 0–20]; C-reactive protein [CRP], 180 mg/L [normal range,0–8]; and ferritin, 323 ng/ml), infection markers positive with 6,3ng/ml of procalcitonine The patient had a renal dysfunction test result and mild derangement in liver function enzymes. raised creatine kinaseMB (CK-MB) at 16.8 ng/ml (normal range, 0.6–6.3 ng/ml) and troponin at 0.12ng/ml (normal, <0.1ng/ml). Immunological tests showed a high positive antinuclear antibodies (ANA, negative anti–double-stranded DNA antibodies.Treatment with iv diuretics was started with probabilistic biantibiotics, the blood culture showed the presence of staphylococcus aurerus probably related to bacteremia, therefore the antibiotic therapy was adapted to the antibiogram the clinical outcome was favorable with persistence of echocardiographic images in conjunction with non-infectious endocarditis, thoracic tdm demonstrated alveolar interstitial involvement and minimal pleurisy. During her hospitalization, the patient presented a constrictive chest pain radiating to the upper limbs, the electrocardiogram showed an st segment elevation in the inferior derivation the patient was loaded with 75 mg of clipidogrel and 300 mg of aspirin, and received two puffs of natispray, the course was the regression of the st segment elevation, probably related to a coronary spasm.

Three days later the patient presented a sudden neurological deficit type of right hemiparesis with facial paralysis and aphasia, the emergency MRI objectified a cortical frontotemporal stroke, in the acute phase, NIHSS score = 12, after decision of the neurological staff and having ruled out infectious endocarditis the patient was thrombolysed by metalysis with monitoring of the NIHSS Score and hemodynamic constants every 15 min finally the diagnosis of vasculitis of the central nervous system (CNS) was retained with ischemic and hemorrhagic lesions in favor of lupus vasculitis of the CNS [Figure 2-4].

Figure 2: MRI image showing a cortical frontotemporal stroke.

Figure 3: Left frontotemporal cortico-subcortical area in diffusion hyper signal.

Figure 4: Nodular flair hyper signals of the subcortical white matter with a vascular appearance.

After multidisciplinary consultation, the patient’s management consisted of:maintaining corticosteroid therapy at a high dose of 60 mg / day with adjuvant treatment stopping plaquenil, In severe, life-threatening conditions, a bolus of solumedrol with cyclophosphamide has been indicated after management of the infectious context of endocarditis.The evolution was marked by a clear improvement in the symptoms with an increase in the left ventricular ejection fractionthe patient was discharged under medical treatment, the patient’s progress was favorable with a marked improvement in quality of life.

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder, characterized by production of autoantibodies directed against nuclear and cytoplasmic antigens, which may affect several different organs.

As in many other autoimmune diseases, either the cause or the underlying pathophysiologic mechanism that triggers the autoimmune response in SLE remains largely unknown, during the following years, new autoantibodies, such as antibodies to DNA (anti-DNA), antibodies to extractable nuclear antigens (nuclear ribonucleoprotein [RNP], Sm, Ro, and La), and anticardiolipin antibodies, were recognized as causative of clinical subsets of lupus. Early genetic studies, driven by the observation of familial SLE aggregation and high concordance in monozygotic twins, have implicated HLA and early complement component genes. Genome wide association studies have identified at least 70 lupus susceptibility loci.

The initial presentation of lupus often mimics a viral syndrome but Systemic lupus may present in many other ways, SLE is an unpredictable disease: it is characterized by alternatingperiods of remission and exacerbation and by a wide variety of clinical manifestations (signs and symptoms) that may affect any organ [7-9].

We report the case of a patient with lupus erythematosus with systemic involvement:

• Cardiac type of lupus myopericadtitis in biventricular dysfunction with LVEF: 25%,

• Hematologic: Normochromic normocytic anemia with positive coombs test and lymphopenia and thrombocytopenia,

• Renal: With glomelus syndrome and at the puncture renal biopsy: lupus nephropathy satde IV

• Neurological: Cerebral vasculitis.

About hematologic manifestations; cytopenias are common in patientswith lupus, and moderate to severe lymphopenia is associatedwith high disease activity and organ damage. Hemolyticanemia is uncommon and is usually associated with disease onset, thrombocytopenia, and African American race [10, 11]. Up to 50% of patients with SLE have evidence of renal disease at presentation. Lupus end-stage kidney disease is associated with worse survival among dialysis and transplant patients compared with other causes of endstage kidney disease. Pleuritis is the most common respiratory SLE manifestation, affecting 30%– 50% of patients.Lupus pleuritic should be diagnosed only after exclusion of other causes of pleural effusion, such as infection, pulmonary embolism, liver disease, heart disease, and cancer. Parenchymal damage is less common and may be caused by interstitial lung disease, acute pneumonitis, or bronchiolitis obliterans with organizing pneumonia. [5, 12-14].

The risk for ischemic stroke is higher in patient with SLE. Stroke affects 3–20% of patients with SLE and usually occurs within the first 5 years of the diagnosis, Several mechanisms are implicated in the pathogenesis of stroke in the setting of SLE including hypercoagulable state due to antiphospholipid antibodies, cardioembolism from marantic endocarditis, enhanced atherosclerosis, and cerebral vasculitis.There is a lack of literature references for the use of thrombolysis in patients presenting with acute ischemic stroke as the manifestation of SLE In one case report,a patient with stroke showed excellent outcome after thrombolysis, which was the first manifestation of undiagnosed SLE. Moreover, lupus anticoagulant is not a contraindication for the use of rt-PA. However, in our case, the stroke was probably primarily due to vasculitis.

Several studies have already demonstrated a clear association between SLE and cardiovascular disease (CVD). The main CVDs of SLE are valvular heart diseases associated with Libman-Sacks disease lesions, sterile vegetations, serositis associated with pericardial disease, and venous and arterialthrombosis associated with antiphospholipid antibodies.It seems that such association between SLE and CVD strictly depends on a combination of several risk factors for CVD, including dyslipidemia and, to a varying degree, hypertension, diabetes, smoking, inflammation, lipid oxidation, antiphospholipid antibodies, and renal disease and renal failure [15-22].There are few case reports of acute myocarditis and heart failure as an initial SLE presentation. The therapeutic approach for myocarditis starts from standard measures with supportive care as first-line therapy, whereas anti-heart failure medications and additional treatment are prescribed on the basis of underlying etiology, African-American patients are at increased risk for development of myocarditis, In more recent post-mortem studies, after the wideuse of corticosteroids in lupus therapeutics, its prevalencewas estimated as 0-8%.Typical clinical features include chest pain with tachycardia, palpitations and/or symptoms of heart failure. Our patient had palpitations and dyspnea. History of recent viral infection is usually absent. Cardiac troponinsand pro-B type natriuretic peptide are often elevated [23-25].

ECG commonly shows sinus tachycardia with widespreadnon- specific ST alterations and T wave changes. It was recently demonstrated that non-specific ST-T changes exist in 31% of newly diagnosed patients.Our patient presented a sinus tachycardia then a st segment elevation.Lupus myocarditis may also present with arrythmias, conduction abnormalities and ventricular dilatation. Low ejection fraction is detected in the majority of the patients. Our patient had an ejection fraction around 25%. Cardiomyopathy in SLE, manifested as global hypokinesis, is multifactorial in its etiology since myocardial dysfunction may be caused by increased global disease activity, concurrent infection, uremia, arterial hypertension, thrombosis and other factors.Chronic antimalarial use (chloroquine or hydroxychloroquine) has been linked to a specific form of cardiomyopathy that resembles that of lysosomal storage diseases. Takotsubo cardiomyopathy was also described in lupus patients [1, 26-30].

The most characteristic valvulopathy of SLE is Libman- Sacks endocarditis (LSE), which mainly affects the left cardiac valves. Our patient presented endocarditis with isolation of a germ in blood culture, this does not exclude a libman sacks associated with bacteremia.Non-steroidal anti-inflammatory drugs (NSAIDs) are considered by most rheumatologists as the first choice in mild cases with minimal pericardial effusion. Corticosteroids should be used in refractory cases with or without antimalarials. it is suggested that this should be 0.5-1mg/kg ofprednisone with a stable dose for a month, followed by slowtapering. Treatment of lupus myocarditis consists of corticosteroidsin high doses (0.5-1mg/kg of prednisone or intravenouspulses of methylprednisolone, e.g. 1000 mg/day for 3 consecutivedays) in combination with immunosuppressives. Cyclophosphamide and intravenous immunoglobulins (IVIGs) have been shown to improve cardiac function and mortality. Ischemic cardiomyopathy should be treated with optimization of antiplatelet/ anticoagulant therapy and supportive measures (angiotensin converting enzyme inhibitors/receptor blockers,beta- blockers, diuretics etc.Our patient was treated with corticosteroid therapy at a high dose of 60 mg / day with adjuvant treatment stopping plaquenil,a bolus of solumedrol with cyclophosphamide has been indicated after management of the infectious context of endocarditisin addition to the medical treatment of Heart failure [1, 2, 26, 31-33].

Lupus is a chronic inflammatory disorder. Diagnosis of SLE can be challenging and while several classification criteria have been posed, their utility in the clinical setting is still a matter of debate. Management of SLE is dictated by organ system involvement, and despite several agents shown to be efficacious in the treatment of SLE, the disease still poses significant morbidity and mortality risk in patients. It leads to a very poor quality of life without appropriate management.To reduce morbidity and mortality, an interprofessional team should educate and manage patients with SLE.

1. Zhang L, Zhu Y-L, Li M-T, Gao N, You X, Wu Q-J et al. “Lupus Myocarditis: A Case–Control Study from China ”. Chinese Med J 128 (2015): 2588-2594.
   
   
2. Marijanovich N and Halalau A. “Hemorrhagic Tamponade as Initial Manifestation of Systemic Lupus with Subsequent Re- fractory and Progressive Lupus Myocarditis Resulting in Car- diomyopathy and Mitral Regurgitation”. Case RepRheumatol (2018): 1-4.
   
   
3. Ball EMA and Bell AL. “Lupus arthritis--do we have a clinical- ly useful classification? “. Rheumatology (Oxford) 51 (2012): 771-779.
   
   
4. Vera-Recabarren MA, García-Carrasco M, Ramos-Casals M, Herrero C. “Comparative analysis of subacute cutaneous lupus erythematosus and chronic cutaneous lupus erythema- tosus: clinical and immunological study of 270 patients“. Br J Dermatol 162 (2010): 91-101.
   
   
5. Kiriakidou M and Ching CL. “Systemic Lupus Erythematosus. Annals of Internal Medicine“. Ann Intern Med 172 (2020): 81-96. 
   
   
6. Thomas G, Cohen Aubart F, Chiche L, Haroche J, Hie M et al. “Lupus Myocarditis: Initial Presentation and Longterm Out- comes in a Multicentric Series of 29 Patients“. J Rheumatol 44 (2017): 24-32.
7. Fortuna G and Brennan MT.“Systemic Lupus Erythematosus“. Dental Clinics of North America 57 (2013): 631-55.
   
   
8. Sestak AL, Fürnrohr BG, Harley JB, Merrill JT, Namjou B. “The genetics of systemic lupus erythematosus and implications for targeted therapy“. Ann Rheum Dis 70 (2011): 37-43.
   
   
9. Jeong DY, Lee SW, Park YH, Choi JH, Kwon YW et al. “Ge- netic variation and systemic lupus erythematosus: A field synopsis and systematic meta-analysis“. Autoimmun Rev 17 (2018) : 553-566.
   
   
10. Vilá LM, Alarcón GS, McGwin G, Bastian HM, Fessler BJ et al. “Systemic lupus erythematosus in a multiethnic US cohort, XXXVII: association of lymphopenia with clinical manifesta- tions, serologic abnormalities, disease activity, and damage accrual“. Arthritis Rheum 55 (2006): 799-806.
    
    
11. Durán S, Apte M, Alarcón GS, Marion MC, Edberg JC et al. “Features associated with, and the impact of, hemolytic ane- mia in patients with systemic lupus erythematosus: LX, results from a multiethnic cohort“. Arthritis Rheum 59 (2008): 1332-1340.
    
    
12. Almaani S, Meara A, Rovin BH. “Update on Lupus Nephritis“. Clin J Am Soc Nephrol 12 (2017) : 825-835.
    
    
13. Zhang L, Lee G, Liu X, Pascoe EM, Badve SV et al. “Long- term outcomes of end-stage kidney disease for patients with lupus nephritis“. Kidney Int 89 (2016): 1337-1345.
    
    
14. Kamen DL and Strange C. “Pulmonary manifestations of systemic lupus erythematosus“. Clin Chest Med 31 (2010): 479-488.
    
    
15. Loannidis S, Mavridis M, Mitsias PD. “Ischemic stroke as initial manifestation of systemic lupus erythematosus: A case report and review of the literature“. NeurolSci 13 (2018): 26-30.
    
    
16. Hanly JG, Li Q, Su L, Urowitz MB, Gordon C et al. “Cerebro- vascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study“. Arthritis Care Res 70 (2018):1478-1487.
    
    
17. Shaban A and Leira EC. “Neurological Complications in Pa- tients with Systemic Lupus Erythematosus“. Curr Neurol Neu- rosci Rep 19 (2019): 97.
    
    
18. Loharia JJ, Alam JM, Abdelhadi HA, Marei TF. “Thrombolyt- ic therapy at systemic lupus onset with secondary antiphos- pholipid syndrome. A rare stroke experience“. Neurosciences 21(2015) : 55-60.
    
    
19. Majdak MR and Vuleti? V. “Thrombolysis for acute stroke in patient with systemic lupus erythematosus: A case report“. J Neurol Sci (2016): 7-8.
    
    
20. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. “Risk factors for coronary artery disease in patients with systemic lupus erythematosus“. Am J Med 93 (1992): 513-519.
    
    
21. Owlia MB, Mostafavi Pour Manshadi SMY, Naderi N. “Cardi- ac Manifestations of Rheumatological Conditions: A Narrative Review“. ISRN Rheumatology (2012): 1-10.
    
    
22. Frostegard J. “SLE, atherosclerosis and cardiovascular dis- ease“. J Intern Med 257 (2005): 485-495.
    
    
23. Baquero G, Banchs JE, Naccarelli GV, Gonzalez M, Wolbrette DL. “Cardiogenic Shock as the Initial Presentation of Systemic Lupus Erythematosus: A Case Report and Review of the Liter- ature“ Congest Heart Fail 18 (2012): 337-341.
    
    
24. Apte M, McGwin G, Vila LM, Kaslow RA, Alarcon GS et al. “Associated factors and impact of myocarditis in patients with SLE from LUMINA, a multiethnic US cohort“. Rheumatology 47 (2007): 362-367.
    
    
25. Miner JJ and Kim AHJ. “Cardiac Manifestations of Systemic Lu- pus Erythematosus“. Rheum Dis Clin North Am 40 (2014): 51-60.
    
    
26. Tselios K and Urowitz MB. “Cardiovascular and Pulmonary Manifestations of Systemic Lupus Erythematosus“. Curr Rheumatol Rev 13 (2017): 206-218.
    
    
27. Bourré-Tessier J, Urowitz MB, Clarke AE, Bernatsky S, Krantz MJ et al. “Electrocardiographic Findings in Systemic Lupus Erythematosus: Data From an International Inception Cohort: Prevalence of EKG Abnormalities in SLE Patients“. Arthritis Care Res 67 (2015): 128-135.
    
    
28. Tincani A, Rebaioli CB, Taglietti M, Shoenfeld Y. “Heart in- volvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus“. Rheumatology 45 (2006): 8-13.
    
    
29. Yogasundaram H, Putko BN, Tien J, Paterson DI, Cujec B, et al. “Hydroxychloroquine-Induced Cardiomyopathy: Case Re- port, Pathophysiology, Diagnosis, and Treatment“. CanJ Car- diol 30 (2014) : 1706-1715.
    
    
30. Shim IK, Kim B-J, Kim H, Lee J-W, Cha T-J et al. “A Case of Persistent Apical Ballooning Complicated by Apical Thrombus in Takotsubo Cardiomyopathy of Systemic Lupus Erythemato- sus Patient“. J Cardiovasc Ultrasound 21 (2013): 137.
    
    
31. Muangchan C, van Vollenhoven RF, Bernatsky SR, Smith CD, Hudson M et al. “Treatment Algorithms in Systemic Lupus Ery- thematosus“. Arthritis Care Res. 67 (2015): 1237-1245.
    
    
32. Kruzliak P, Novak M, Piler P, Kovacova G. “Pericardial involve- ment in systemic lupus erythematosus: current diagnosis and therapy“. Acta Cardiol 68 (2013): 629-633.
    
    
33. Fihn SD, Blankenship JC, Alexander KP, Bittl JA, Byrne JG et al. “2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Up- date of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease“. J Am College Cardiol 64 (2014): 929-949.